161 results
Page 3 of 9
8-K
EX-99.1
jtqioxx8 ma02j
9 Nov 21
Intra-cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-99.1
u41k4bk5
9 Aug 21
Intra-cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
2lb3kuqw77b0osipzb3
10 May 21
Intra-cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
lr786xvxcxs 9w6ncam
3 May 21
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
7:42am
DEFA14A
vabh1e
20 Apr 21
Additional proxy soliciting materials
7:07am
PRE 14A
zr7atar4mc 4y
19 Apr 21
Preliminary proxy
5:28pm
8-K
EX-99.1
hr6bs8bnn5qg31fsjryw
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am
8-K
EX-99.1
37dnhh39
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am
8-K
EX-99.1
vz5efxq2uoy 9ljebmt8
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
8-K
EX-1.1
ewppjd1
11 Sep 20
Entry into a Material Definitive Agreement
4:47pm
424B5
l1zo7
11 Sep 20
Prospectus supplement for primary offering
4:44pm
8-K
EX-99.2
chv9fn 5veuxmjflh
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
424B5
vd2uhc180vmsk
9 Sep 20
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
cwyd7axxjnxs80xv
9 Sep 20
Intra-Cellular Therapies Announces Positive Topline Results
7:13am